Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

tments pledged to a bank as collateral for two letters of credit; the first in the amount of $6,000,000 was issued in connection with the potentially refundable upfront payment received under the collaboration agreement with Centocor and the second in the amount of CDN$640,000 was granted in favour of a landlord in relation to the lease of a building. As at December 31, 2007, restricted cash is composed of third-party Asset-Backed Commercial Paper (ABCP). These investments were due to mature during the second quarter of 2007 but, as a result of a disruption in the credit markets, particularly in the ABCP market, they did not settle on maturity and currently remain outstanding. At the time these investments were acquired, the ABCP were rated R1-high by Dominion Bond Rating Service, which is the highest credit rating for this type of investment. The ABCP are currently subject to a restructuring proposal under a standstill agreement which is expected to result in the conversion of the ABCP into longer-term financial instruments with maturities corresponding to the underlying assets. A Pan-Canadian Investors Committee (the Committee) was established to oversee the orderly restructuring of these instruments during this standstill period. A restructuring plan was announced by the Committee on December 23, 2007, and is anticipated to be completed by the end of March, 2008. During the quarter ended December 31, 2007, the Company recorded a provision for losses in the amount of $1,184,000 in respect of ABCP, reflecting the Company's estimated reduction in the fair value of these investments as at December 31, 2007. The Company estimated the fair value of the ABCP using a probability weighted discounted cash flow approach, based on its best estimates of the time period over which the assets are going to generate cash flows ranging from 7 to 30 years based on the proposed restructuring, the coupon interest rate, the discount rate to apply to the net cash flows anticipated to b
'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... July 13, 2014 Fuel additives are ... gasoline, diesel, jet fuel, kerosene, and so on, in ... responsible for reducing the corrosion effects caused by fuels ... added to any fuel, provide economies of scale in ... escalate the overall cost of the fuel products. , ...
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, ... for people with diabetes is being developed to measure sugar ... report. Scientists at Brown University in Providence, R.I., created ... uses light, metal and a special enzyme that changes color ... have to prick their fingers to draw blood to check ...
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
Breaking Medicine News(10 mins):Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
... and Crest/Oral-B Survey Unveiled at ... 2008 The American Dental,Association (ADA(R)), in collaboration with Crest(R) and ... care., Here is a sneak peek at the key ... of one,s mouth, teeth and gums is ...
... 2008/2009 survey of more than 5,500 benefit plans found 68.3 percent of ... increasing the employee portion of the premium. , ... Kansas City, KS ... containment and cost reduction measures to combat rising health care costs. The ...
... test to identify those most at risk from hair loss is now ... ... (PRWEB) October 17, 2008 -- A groundbreaking genetic test to identify those ... for both men and women. , , ,Currently only available at ...
... Year 2020, Food Companies Will Be Expected to Cede ... Oct. 16 Today,s consumers want to have a,greater ... the year,2020, consumers around the globe expect the way ... to a recent study of consumers in five,countries., ...
... Consumers, FALLS CHURCH, Va., Oct. 16 ... of digestive health issue (*see reference,below). The issue ... in,which prebiotics and probiotics could benefit them. For ... for prebiotics and,probiotics by working with a truly ...
... Oct. 16 Americans United for Life,(AUL) today filed ... Ohio,s regulation of the deadly abortion drug, RU-486., ... proven track,record of ruining and even ending women,s lives. ... of this drug. Ohio,s statute is a,step in the ...
Cached Medicine News:Health News:New National Public Opinion Survey Reveals Important Findings on Oral Health Care Perceptions 2Health News:New National Public Opinion Survey Reveals Important Findings on Oral Health Care Perceptions 3Health News:Employers' Methods for Containing and Reducing Costs Vary By Region 2Health News:Employers' Methods for Containing and Reducing Costs Vary By Region 3Health News:Breakthrough Baldness Genetic Test 2Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 2Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 3Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 4Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 5Health News:MyHealthGate, Inc. Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 2Health News:Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 2
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Inc. (Nasdaq: MSON ), a developer of minimally invasive ... the ablation of tumors and worldwide for other acute health ... year ended June 30, 2009. , The Company also reported ... payment of $3.5 million was received on April 7, 2009 ...
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3
... Aplicare's Saturated Swabsticks are packaged ... Each 4 inch Swabstick is saturated ... solution. Each package is terminally sterilized, ... the patient. Povidone Iodine Scrub is ...
... 70% alcohol and 10% povidone iodine ... forming a barrier on the skin. ... for the povidone iodine, giving persistent ... with catheter related infections for up ...
... Aplicare's Saturated Swabsticks are ... single-use foil-laminated pouches. Each ... saturated with precisely the ... Each package is terminally ...
Triad Plus PVP-I Prep Solution has broad-spectrum germicidal action. Povidone Iodine Solution using an innovative one-piece screw cap, Triad Plus bottles are designed specifically to meet the needs o...
Medicine Products: